Navigation Links
Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
Date:2/12/2009

Earns Milestone Payment of Additional $2.5 Million

CRANBURY, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Alternext US: PTN) today announced it has received $4.1 million from AstraZeneca relating to an extension of its exclusive research collaboration and license agreement to discover, develop and commercialize compounds that target melanocortin receptors and a clinical trial sponsored research agreement.

Palatin also announced that it has earned a milestone payment of $2.5 million in connection with its collaboration and license agreement with AstraZeneca. Palatin anticipates receiving the $2.5 million in the current calendar quarter.

The $6.6 million received or to be received from AstraZeneca, coupled with $1.7 million that Palatin received from the sale of net operating losses to the State of New Jersey, $700,000 from the sale of non-core fixed assets, and its cash and cash equivalents balance, gives Palatin sufficient cash to fund its projected operations through calendar year 2009.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at www.palatin.com.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
2. Palatin Technologies to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
3. Stratus Technologies Partners With Infinity Healthcare Solutions to Resell Availability Products With Its Services
4. Dilon Technologies Leads Molecular Breast Imaging Expansion
5. China Medical Technologies to Announce Financial Results for the Third Fiscal Quarter Ended December 31, 2008 on March 2, 2009
6. VNUS Medical Technologies to Present at the Roth 21st Annual OC Growth Stock Conference
7. Greenway Medical Technologies and Navicure Form Partnership to Streamline Claims Management Process
8. ReBuilder Medical Technologies, Inc. to Change Name to American Med Tech
9. Advanced Wound Technologies Mid-Atlantic, Inc. Announces Name Change and Reverse Stock Split
10. ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09
11. Scribe Healthcare Technologies, LLC to Integrate BenchMark KB™ in Scribe Complete™ Medical Documentation Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... brain injury specialists look back on 40 years of the ... scale in research and clinical practice, in a new Personal ... , The Personal View is published on the 40th ... Lancet article*. Since this seminal publication, the Glasgow Coma ... impairment of conscious level, the clinical hallmark of acute brain ...
(Date:7/14/2014)... 2014 A recent study published in the July ... Academy of Child and Adolescent Psychiatry confirms the ... onset criterion for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , ... set at 7 in DSM-IV, has been raised to ... now set at 12, rather than an earlier age, ...
(Date:7/14/2014)... the company Tissuegnostics, the pathologist Lukas Kenner and his ... identify cancer cells in tissue sections and demonstrate the ... provides a precise picture of the disease and leads ... the results of the study, "Two independent pathologists concur ... diagnosis." , "The recently developed software offers, for the ...
(Date:7/14/2014)... and Hauppauge, NY (PRWEB) July 14, 2014 ... (RGONY), with offices in Hicksville and Hauppauge, NY, ... implant) as a long-lasting treatment for diabetic macular ... Allergan, recently obtained an additional FDA-approved indication for ... approved by the FDA in 2009 for treatment ...
(Date:7/14/2014)... There’s an old adage that says first ... Palette say the products offered in their preorder event ... can reserve The Lash Palette for $40,” said Jenelle Paris, ... , Paris explained that the first 1,000 have already been ... She went on to point out that her company is ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3Health News:The Lash Palette Preorder Event Has Officially Begun 2
... , , Improvement ... ROSEMONT, Ill., Aug. 3 A new study published in ... Joint Surgery (JBJS) finds that two years after anterior cervical ... can be expected to have significant improvement in their headache symptoms. , ...
... LOUIS, Aug. 3 Not just for teens anymore--social networking and ... by adults to interact with their friends, families and to gain ... these tools to the list of ways to interact with their ... its members like never before, Anthem Blue Cross and Blue Shield ...
... Hard to Treat Diseases, Inc. (HTDS:PK), http://www.htdsmedical.com ... division have reported results on experiments in which ... after traumatic brain injury have been explored. These ... the Hyperbaric Medical Center, School of Medicine, University ...
... The ... Harper, Jason Mraz, G. Love & others , ... Los Angeles, CA (PRWEB) August 3, 2009 -- Domestix, a Beverly Hills based domestic sales ... Thursday, August 6th at the Malibu Cinemas. "Domestix is thrilled to be involved with Jesse,s Story. ...
... PLAINSBORO, N.J., Aug. 3 Pharmacy & Healthcare Communications, LLC ... Pharmacy Times , a monthly journal that reaches the ... as well as its website, www.PharmacyTimes.com , ... custom supplements, including Pharmacy Times Careers ...
... By injecting man-made, microscopic tubes into tumors and heating ... have discovered a way to effectively kill kidney tumors in ... suggests a potential future cancer treatment for humans. The ... of the National Academy of Sciences ). It is the ...
Cached Medicine News:Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 2Health News:Neck Surgery for Cervical Spine Disorders Found to Alleviate Associated Headaches 3Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 2Health News:Anthem Blue Cross and Blue Shield in Missouri Harnesses Social Media to Interact with Members 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 2Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 3Health News:Hard to Treat Diseases, Inc. (HTDS) Experiments with Hyperbaric Oxygenation (HBO) Traumatic Brain Injury 4Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 2Health News:"Jesse's Story" to Open The 10th Annual Malibu Film Festival 3Health News:Pharmacy Times Names New Editorial Director 2Health News:Researchers effectively treat tumors with use of nanotubes 2Health News:Researchers effectively treat tumors with use of nanotubes 3
(Date:7/14/2014)... Ala. , July 14, 2014  Patients and ... patients as Express Scripts and other major pharmacy benefit ... The cuts will directly impact millions of patients who ... medical conditions, including persistent pain from cancer, diabetes and ... begin notifying some patients on July 15. ...
(Date:7/14/2014)... , 14 de julio de 2014 /PRNewswire-HISPANIC PR WIRE/ ... que Barry Epling , presidente de la junta ... de la Compañía. El señor Epling es el dueño ... otorgó la licencia de su formulación, sus propiedades intelectuales ... de apoyo financiero. "El señor Gerald ...
(Date:7/14/2014)... CITY , July 14, 2014  Remedy ... software for healthcare delivery and life sciences research, ... National Pancreas Foundation (NPF) to build the first-ever ... including pancreatic cancer and pancreatitis. "The ... the evolutionary change that thoughtful and committed organizations ...
Breaking Medicine Technology:Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4BioAdaptives se prepara para el próximo paso 2BioAdaptives se prepara para el próximo paso 3Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 2Remedy Informatics Partners with National Pancreas Foundation to Build a National Patient Registry 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: